

Closing Remarks

October 27, 2020

Sudhir Sivakumaran, Executive Director, CPAD

The Journey Continues…

- Integrating data from multiple sources into a standardized and centralized repository is the solid foundation upon which we can generate novel quantitative and analytical tools and solutions
- Effective and efficient clinical trial design with better patient stratification, and use of established and validated efficacy endpoints
- Accounting for and promoting diversity in future clinical trials
- Better understanding of what matters most to patients and what are the most clinically meaningful measures for tracking disease progression and treatment efficacy

www.c-path.org/

CRITICAL PATH INSTITUTE

Thank you!

Pharmaceutical Industry

AbbVie Inc.
Biogen
Boehringer Ingelheim Pharmaceuticals Inc.
Eisai
Eli Lilly and Company
F. Hoffman La Roche
IXICO plc.
Janssen Research & Development LLC
Merck, Sharp & Dohme Corporation
Novartis Pharmaceuticals Corporation
Oxford Brain Diagnostics
Takeda Pharmaceuticals
Unlearn.AI, Inc
vTv Therapeutics

CPAD
CRITICAL PATH FOR ALZHEIMER'S DISEASE
CRITICAL PATH INSTITUTE

Government and Regulatory Agencies

European Medicines Agency (EMA)
National Institute on Aging (NIA)
National Institutes of Health (NIH)
National Institute of Neurological Disorders and Stroke (NINDS)
U.S. Food and Drug Administration (FDA)

Non-profit research Organizations

Alzheimer's Association
Alzheimer's Drug Discovery Foundation
Alzheimer's Research UK
CHDI Foundation
UsAgainstAlzheimer's

Critical Path Institute is supported by the Food and Drug Administration (FDA) of the U.S. Department of Health and Human Services (HHS) and is 62% funded by FDA/HHS, totaling $14,448,917, and 38% percent funded by non-government source(s), totaling $8,669,646. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, FDA/HHS or the U.S. Government.

CPAD Team

- **Sudhir Sivakumaran**, Executive Director, CPAD
- **Nathan Hanan**, Scientific Director of Pharmacometrics, Quantitative Medicine
- **Klaus Romero**, CSO, C-Path
- **Jackson Burton**, Executive Director, Quantitative Medicine
- **Yashmin Karten**, Sr. Project Manager, CPAD
- **Eileen Priest**, Project Coordinator, CPAD
- **Zihan Cui**, Developer, Quantitative Medicine
- **Hazel White**, Intern, CPAD
- **Vanda Molnar**, Data Manager, CPAD
- **Bob Stafford**, Sr. Data Specialist, Data Programming Team Lead, Data Collaboration Center
- **Jagdeep Podichetty**, Scientific Director, Quantitative Medicine
- **Maedeh Beheshti**, Postdoctoral Fellow, Artificial Intelligence (AI)
- **Joseph Scheeren**, President & CEO, C-Path